In the busiest week yet for the 2020 IPO market, 15 IPOs raised $8.7 billion. Snowflake (SNOW) took the spotlight, completing the largest software IPO ever and bagging the biggest billion-dollar pop in two decades. Eight SPACs joined the...read more
COMPASS Pathways, a British Phase 2 biotech developing a psilocybin-based therapy for depression, raised $128 million by offering 7.5 million ADSs at $17, above the range of $14 to $16. The company offered 0.8 million more ADSs than anticipated. At pricing, the...read more
COMPASS Pathways, a British Phase 2 biotech developing a psilocybin-based therapy for depression, announced terms for its IPO on Monday. The Cheshire, United Kingdom-based company plans to raise $101 million by offering 6.7 million shares at a price range...read more
COMPASS Pathways, a British Phase 2 biotech developing a psilocybin-based therapy for depression, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company is focusing on using its proprietary formulation of...read more
US IPO Weekly Recap: Snowflake's IPO breaks records in a diverse 15 IPO week
In the busiest week yet for the 2020 IPO market, 15 IPOs raised $8.7 billion. Snowflake (SNOW) took the spotlight, completing the largest software IPO ever and bagging the biggest billion-dollar pop in two decades. Eight SPACs joined the...read more
Can magic mushrooms treat depression? Biotech COMPASS Pathways prices upsized US IPO above the range at $17
COMPASS Pathways, a British Phase 2 biotech developing a psilocybin-based therapy for depression, raised $128 million by offering 7.5 million ADSs at $17, above the range of $14 to $16. The company offered 0.8 million more ADSs than anticipated. At pricing, the...read more
Psilocybin biotech COMPASS Pathways sets terms for $101 million US IPO
COMPASS Pathways, a British Phase 2 biotech developing a psilocybin-based therapy for depression, announced terms for its IPO on Monday. The Cheshire, United Kingdom-based company plans to raise $101 million by offering 6.7 million shares at a price range...read more
British Phase 2 psilocybin biotech COMPASS Pathways files for a $100 million IPO
COMPASS Pathways, a British Phase 2 biotech developing a psilocybin-based therapy for depression, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company is focusing on using its proprietary formulation of...read more